CYTH vs. CLYM, ENTA, SKYE, ATOS, XBIT, ALGS, EDIT, ZURA, ARTV, and ANIX
Should you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include Climb Bio (CLYM), Enanta Pharmaceuticals (ENTA), Skye Bioscience (SKYE), Atossa Therapeutics (ATOS), XBiotech (XBIT), Aligos Therapeutics (ALGS), Editas Medicine (EDIT), Zura Bio (ZURA), Artiva Biotherapeutics (ARTV), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry.
Cyclo Therapeutics vs.
Cyclo Therapeutics (NASDAQ:CYTH) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.
Cyclo Therapeutics received 8 more outperform votes than Climb Bio when rated by MarketBeat users. However, 100.00% of users gave Climb Bio an outperform vote while only 71.43% of users gave Cyclo Therapeutics an outperform vote.
Climb Bio has a net margin of 0.00% compared to Cyclo Therapeutics' net margin of -2,847.19%. Cyclo Therapeutics' return on equity of 0.00% beat Climb Bio's return on equity.
Cyclo Therapeutics currently has a consensus target price of $0.95, indicating a potential upside of 4.42%. Climb Bio has a consensus target price of $10.00, indicating a potential upside of 568.90%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts plainly believe Climb Bio is more favorable than Cyclo Therapeutics.
In the previous week, Cyclo Therapeutics had 1 more articles in the media than Climb Bio. MarketBeat recorded 1 mentions for Cyclo Therapeutics and 0 mentions for Climb Bio. Cyclo Therapeutics' average media sentiment score of 0.00 equaled Climb Bio'saverage media sentiment score.
68.6% of Cyclo Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 29.8% of Cyclo Therapeutics shares are owned by company insiders. Comparatively, 3.2% of Climb Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Cyclo Therapeutics has higher revenue and earnings than Climb Bio. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.
Cyclo Therapeutics has a beta of -0.49, meaning that its share price is 149% less volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500.
Summary
Climb Bio beats Cyclo Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Cyclo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CYTH) was last updated on 2/22/2025 by MarketBeat.com Staff
